The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Summary Increasing lines of evidence indicate that obesity is an important risk factor for the exacerbation of alcoholic liver disease (ALD) and nonalcoholic steatohepatitis (NASH). Leptin, an obese gene product, is a cytokine-type hormone mainly produced from adipose tissue. Recently, it has been demonstrated that serum leptin levels are increased in patients with alcoholic cirrhosis. In this study,...
Treatment of non‐alcoholic fatty liver disease involves not only the management of the liver disease itself but the associated metabolic risk factors as well. However, no single treatment has been shown to be universally efficacious. Effective treatment regimens directed at both decreasing insulin resistance as well as the processes of necroinflammation have been investigated and include lifestyle...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.